XML 58 R47.htm IDEA: XBRL DOCUMENT v3.25.2
Segment - Net Income as Profit Measure (Details)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2025
USD ($)
segment
Jun. 30, 2024
USD ($)
Segment Reporting Information [Line Items]        
Number of reporting segments | segment     1  
Revenue:        
Total revenue $ 130,164 $ 114,428 $ 244,637 $ 211,272
Cost of revenue:        
Intangible asset amortization - cost of revenue 2,667 2,909 5,252 5,824
Gross profit 89,769 77,913 169,277 140,381
Operating expenses:        
Total research and development 16,264 16,465 33,984 32,430
Total selling and marketing 25,316 24,216 49,770 47,998
Total general and administrative 32,331 31,745 66,139 57,955
Impairment of assets 20,505 0 20,505 429
Other income, net (6,518) (2,755) (11,042) (5,503)
Income tax provision 2,230 1,627 2,611 1,583
Net income (loss) (980) 5,734 6,067 3,870
Testing revenue        
Revenue:        
Total revenue 122,263 106,970 229,572 197,273
Cost of revenue:        
Cost of revenue 32,407 27,920 60,667 53,899
Product revenue        
Revenue:        
Total revenue 3,598 3,906 7,178 7,443
Cost of revenue:        
Cost of revenue 1,749 1,874 3,171 4,518
Biopharmaceutical and other revenue        
Revenue:        
Total revenue 4,303 3,552 7,887 6,556
Cost of revenue:        
Cost of revenue 3,572 3,812 6,270 6,650
Intangible Asset Amortization        
Operating expenses:        
Intangible asset amortization - operating expenses 621 881 1,243 1,619
Reportable Segment        
Revenue:        
Total revenue 130,164 114,428 244,637 211,272
Cost of revenue:        
Intangible asset amortization - cost of revenue 2,667 2,909 5,252 5,824
Gross profit 89,769 77,913 169,277 140,381
Operating expenses:        
Total research and development 16,264 16,465 33,984 32,430
Total selling and marketing 25,316 24,216 49,770 47,998
Total general and administrative 32,331 31,745 66,139 57,955
Impairment of assets 20,505 0 20,505 429
Other income, net (6,518) (2,755) (11,042) (5,503)
Income tax provision 2,230 1,627 2,611 1,583
Net income (loss) (980) 5,734 6,067 3,870
Reportable Segment | Research and development:        
Operating expenses:        
Compensation expense 9,063 8,365 18,812 17,450
Direct expense 3,292 5,243 7,434 9,117
Other research and development expenses 1,880 1,339 3,692 2,857
Allocation of facilities and IT expenses 2,029 1,518 4,046 3,006
Reportable Segment | Selling and marketing:        
Operating expenses:        
Compensation expense 17,601 17,081 35,236 34,703
Direct expense 1,478 2,048 2,188 3,186
Other selling and marketing expenses 3,696 3,212 7,549 6,627
Allocation of facilities and IT expenses 2,541 1,875 4,797 3,482
Reportable Segment | General and administrative:        
Operating expenses:        
Compensation expense 21,260 23,107 41,433 40,866
Other general and administrative expenses 19,734 15,444 41,624 30,481
Allocation of facilities and IT expenses (8,663) (6,806) (16,918) (13,392)
Reportable Segment | Testing revenue        
Revenue:        
Total revenue 122,263 106,970 229,572 197,273
Cost of revenue:        
Laboratory supplies and reagents expense 15,304 13,326 28,369 25,244
Sample collection expense 3,494 3,164 6,320 6,221
Compensation expense 6,023 5,139 11,634 10,354
Other cost 4,173 3,479 7,559 6,325
Allocation of facilities and IT expenses 3,413 2,812 6,785 5,755
Cost of revenue 32,407 27,920 60,667 53,899
Reportable Segment | Product revenue        
Revenue:        
Total revenue 3,598 3,906 7,178 7,443
Cost of revenue:        
Product costs 705 628 813 1,891
License fees and royalties 307 314 631 751
Other cost 515 800 1,309 1,623
Allocation of facilities and IT expenses 222 132 418 253
Cost of revenue 1,749 1,874 3,171 4,518
Reportable Segment | Biopharmaceutical and other revenue        
Revenue:        
Total revenue 4,303 3,552 7,887 6,556
Cost of revenue:        
Compensation expense 1,652 2,072 2,892 3,533
Other cost 1,462 1,271 2,506 2,221
Allocation of facilities and IT expenses 458 469 872 896
Cost of revenue 3,572 3,812 6,270 6,650
Reportable Segment | Intangible Asset Amortization        
Operating expenses:        
Intangible asset amortization - operating expenses $ 621 $ 881 $ 1,243 $ 1,619